Brookline Capital Markets launched coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $9 price target. The stock closed at $1.79 on July 25. Celsion is focused on clinical-stage oncology products and platform...
By Len Zehr Ali Tehrani, President and CEO Zymeworks’ (NYSE, TSX:ZYME) marquee partnerships with Merck, Eli Lilly, Celgene, GlaxoSmithKline and Daiichi-Sankyo provide validation for its next-generation oncology...
By Len Zehr As chief scientific officer, EVP and head of closely held Triphase Accelerator, Mohit Trikha has parlayed a successful 20-year track record in oncology drug development into a home run, selling Triphase’s...
By Len Zehr A new sales and marketing venture with a unit of Mission Pharmacal gives DARA BioSciences (NASDAQ:DARA) a formidable leg up in the oncology supportive care sector to address ongoing areas of medical need. A...